Clarithromycin (Biaxin) extended-release tablet: a therapeutic review
Abstract
Clarithromycin (Biaxin) extended-release tablets, an advanced generation macrolide, were recently introduced into the USA for the treatment of acute exacerbations of chronic bronchitis, community-acquired pneumonia and acute maxillary sinusitis. The reformulation is intended to improve both patient compliance and tolerability. The extended-release tablets allow convenient once-daily dosing (1000 mg). The extended-release formulation has been shown to be equivalent to the immediate-release formulation concerning area under the plasma concentration time curve. In comparative clinical trials for acute exacerbations of chronic bronchitis, community-acquired pneumonia and acute maxillary sinusitis, clarithromycin extended-release tablets were equivalent to the immediate-release formulation concerning clinical efficacy and bacterial eradication, with improved gastrointestinal tolerability. Similar efficacy and gastrointestinal tolerability results were demonstrated in a recent comparative study of clarithromycin extended-release formulation and amoxicillin-clavulanate in patients with acute exacerbations of chronic bronchitis. Clarithromycin extended-release 1000 mg daily has also been shown to be equivalent to levofloxacin 500 mg daily for the treatment of community-acquired pneumonia in a recent study. The macrolide class of antimicrobials, including clarithromycin extended-release, continues to be a safe and efficacious choice for the out-patient management of…
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.